Respiri Valuation

Is RSH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RSH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RSH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RSH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RSH?

Key metric: As RSH barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RSH. This is calculated by dividing RSH's market cap by their current book value.
What is RSH's PB Ratio?
PB Ratio	39.2x
Book	AU$2.64m
Market Cap	AU$105.86m

RSH key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	102.3x
Enterprise Value/EBITDA	-15.1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does RSH's PB Ratio compare to its peers?

The above table shows the PB ratio for RSH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	12.9x
IPD ImpediMed	2.7x	67.5%	AU$107.2m
OIL Optiscan Imaging	9.6x	n/a	AU$137.8m
CYC Cyclopharm	3.2x	104.9%	AU$152.8m
AVR Anteris Technologies	36x	-24.1%	AU$194.9m
RSH Respiri	39.2x	n/a	AU$105.9m

Price-To-Book vs Peers: RSH is expensive based on its Price-To-Book Ratio (39.2x) compared to the peer average (12.9x).

Price to Book Ratio vs Industry

How does RSH's PB Ratio compare vs other companies in the AU Medical Equipment Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
OSP Osprey Medical	0.7x	n/a	US$3.57m
OVN Oventus Medical	0.6x	n/a	US$3.31m
VIP VIP Gloves	0.2x	n/a	US$1.56m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: RSH is expensive based on its Price-To-Book Ratio (39.2x) compared to the Australian Medical Equipment industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is RSH's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RSH PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	39.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RSH's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.02

22.9%

Doctor Care Anywhere Group

AU$25.7m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.065

-3.0%

32.7%

Nova Eye Medical

AU$36.6m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.16

3.2%

14.3%